LSTA
Lisata Therapeutics, Inc. (LSTA) SWOT Analysis Analysis (2026)
Strengths
Strong liquidity with a current ratio of 3.69 and cash ratio of 3.50.
Gross profit margin remains very high at 95%, indicating the core product/service still carries strong unit economics.
Balance sheet leverage appears minimal, with debt-to-equity and debt-to-assets both at 0.
Weaknesses
TTM profitability is deeply negative, with net profit margin at -146.21% and EBIT margin at -160.71%.
Operating efficiency is extremely weak, with asset turnover at 0.01 and working capital turnover at 0.01.
Cash generation is negative, as operating cash flow per share is -1.35 and free cash flow per share is -1.35.
Cost structure is heavily burdened by SG&A at 116.44% of revenue and R&D at 48.81% of revenue.
Opportunities
If revenue scales meaningfully, the high gross margin could support operating leverage.
The company has no debt, which preserves flexibility for financing growth or restructuring if needed.
A current ratio above 3.0 provides near-term runway to execute on a turnaround.
Threats
Persistent losses and negative free cash flow create ongoing going-concern and dilution risk.
Extremely poor cash conversion cycle metrics, including days of sales outstanding at 730 and a negative cash conversion cycle, point to severe working-capital strain.
The valuation remains highly stretched on sales, with EV/sales at 47.65 and price/sales at 152.08 despite negative earnings.
Overall Score
Monthly Update
No material changes this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

